Literature DB >> 20574778

Electronegative low-density lipoprotein is associated with dense low-density lipoprotein in subjects with different levels of cardiovascular risk.

Ana Paula de Queiroz Mello1, Isis Tande da Silva, Aline Silva Oliveira, Valéria Sutti Nunes, Dulcineia Saes Parra Abdalla, Magnus Gidlund, Nágila Raquel Teixeira Damasceno.   

Abstract

Dyslipidemias and physicochemical changes in low-density lipoprotein (LDL) are very important factors for the development of coronary artery disease (CAD). However, pathophysiological properties of electronegative low-density lipoprotein [LDL(-)] remain a controversial issue. Our objective was to investigate LDL(-) content in LDL and its subfractions (phenotypes A and B) of subjects with different cardiovascular risk. Seventy-three subjects were randomized into three groups: normolipidemic (N; n = 30) and hypercholesterolemic (HC; n = 33) subjects and patients with CAD (n = 10). After fasting, blood samples were collected and total, dense and light LDL were isolated. LDL(-) content in total LDL and its subfractions was determined by ELISA. LDL(-) content in total LDL was lower in the N group as compared to the HC (P < 0.001) and CAD (P = 0.006) groups. In the total sample and in those of the N, HC, and CAD groups, LDL(-) content in dense LDL was higher than in light LDL (P = 0.001, 0.001, 0.001, and 0.033, respectively) The impact of LDL(-) on cardiovascular risk was reinforced when LDL(-) content in LDL showed itself to have a positive association with total cholesterol (beta = 0.003; P < 0.001), LDL-C (beta = 0.003; p < 0.001), and non-HDL-C (beta = 0.003; P < 0.001) and a negative association with HDL-C (beta = -0.32; P = 0.04). Therefore, LDL(-) is an important biomarker that showed association with the lipid profile and the level of cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20574778     DOI: 10.1007/s11745-010-3439-7

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  27 in total

1.  Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease.

Authors:  S Toshima; A Hasegawa; M Kurabayashi; H Itabe; T Takano; J Sugano; K Shimamura; J Kimura; I Michishita; T Suzuki; R Nagai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-10       Impact factor: 8.311

2.  Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

Authors: 
Journal:  Diabet Med       Date:  2006-06       Impact factor: 4.359

Review 3.  [LDL: from metabolic syndrome to instability of the atherosclerotic plaque].

Authors:  Antonela F A Siqueira; Dulcinéia S P Abdalla; Sandra R G Ferreira
Journal:  Arq Bras Endocrinol Metabol       Date:  2006-05-23

4.  Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease.

Authors:  Manfredi Rizzo; Vincenzo Pernice; Arian Frasheri; Kaspar Berneis
Journal:  Atherosclerosis       Date:  2007-05-07       Impact factor: 5.162

5.  Charge properties of low density lipoprotein subclasses.

Authors:  M La Belle; P J Blanche; R M Krauss
Journal:  J Lipid Res       Date:  1997-04       Impact factor: 5.922

6.  Minimally modified electronegative LDL and its autoantibodies in acute and chronic coronary syndromes.

Authors:  Jair A Oliveira; Alex Sevanian; Ricardo J Rodrigues; Elaine Apolinário; Dulcineia S P Abdalla
Journal:  Clin Biochem       Date:  2006-05-19       Impact factor: 3.281

7.  Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis.

Authors:  O Ziouzenkova; L Asatryan; M Akmal; C Tetta; M L Wratten; G Loseto-Wich; G Jürgens; J Heinecke; A Sevanian
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

8.  Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2).

Authors:  John W Gaubatz; Baiba K Gillard; John B Massey; Ron C Hoogeveen; Max Huang; Eric E Lloyd; Joe L Raya; Chao-Yuh Yang; Henry J Pownall
Journal:  J Lipid Res       Date:  2006-11-13       Impact factor: 5.922

Review 9.  Metabolic origins and clinical significance of LDL heterogeneity.

Authors:  Kaspar K Berneis; Ronald M Krauss
Journal:  J Lipid Res       Date:  2002-09       Impact factor: 5.922

10.  Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-).

Authors:  H N Hodis; D M Kramsch; P Avogaro; G Bittolo-Bon; G Cazzolato; J Hwang; H Peterson; A Sevanian
Journal:  J Lipid Res       Date:  1994-04       Impact factor: 5.922

View more
  8 in total

1.  Negatively charged low-density lipoprotein is associated with atherogenic risk in hypertensive patients.

Authors:  Jungo Urata; Satoshi Ikeda; Seiji Koga; Tomoo Nakata; Tomohiko Yasunaga; Koichiro Sonoda; Yuji Koide; Naoto Ashizawa; Shigeru Kohno; Koji Maemura
Journal:  Heart Vessels       Date:  2011-04-14       Impact factor: 2.037

2.  The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia.

Authors:  Hüseyin Avni Uydu; Sermet Yıldırmış; Cihan Orem; Mustafa Calapoglu; Ahmet Alver; Birgül Kural; Asım Orem
Journal:  J Membr Biol       Date:  2012-06-16       Impact factor: 1.843

3.  Clinical proteomics identifies urinary CD14 as a potential biomarker for diagnosis of stable coronary artery disease.

Authors:  Min-Yi Lee; Chun-Hao Huang; Chao-Jen Kuo; Chen-Lung Steve Lin; Wen-Ter Lai; Shyh-Horng Chiou
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

4.  Green-banana biomass consumption by diabetic patients improves plasma low-density lipoprotein particle functionality.

Authors:  Zahra Lotfollahi; Ana Paula de Queiroz Mello; Edna S Costa; Cristiano L P Oliveira; Nagila R T Damasceno; Maria Cristina Izar; Antonio Martins Figueiredo Neto
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

5.  Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.

Authors:  Jan Borén; M John Chapman; Ronald M Krauss; Chris J Packard; Jacob F Bentzon; Christoph J Binder; Mat J Daemen; Linda L Demer; Robert A Hegele; Stephen J Nicholls; Børge G Nordestgaard; Gerald F Watts; Eric Bruckert; Sergio Fazio; Brian A Ference; Ian Graham; Jay D Horton; Ulf Landmesser; Ulrich Laufs; Luis Masana; Gerard Pasterkamp; Frederick J Raal; Kausik K Ray; Heribert Schunkert; Marja-Riitta Taskinen; Bart van de Sluis; Olov Wiklund; Lale Tokgozoglu; Alberico L Catapano; Henry N Ginsberg
Journal:  Eur Heart J       Date:  2020-06-21       Impact factor: 29.983

Review 6.  Opinion: On the Way towards the New Paradigm of Atherosclerosis.

Authors:  Alexander A Mironov; Galina V Beznoussenko
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

Review 7.  Electronegative LDL: a circulating modified LDL with a role in inflammation.

Authors:  Montserrat Estruch; José Luis Sánchez-Quesada; Jordi Ordóñez Llanos; Sònia Benítez
Journal:  Mediators Inflamm       Date:  2013-08-22       Impact factor: 4.711

8.  Effect of 405 nm low intensity irradiation on the absorption spectrum of in-vitro hyperlipidemia blood.

Authors:  Hong Wang; Weichao Liu; Xiang Fang; Haichen Wang; Wenjiang Ma; Huajiang Dong; Huijuan Yin; Ying-Xin Li; Hong Sha
Journal:  Technol Health Care       Date:  2018       Impact factor: 1.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.